Teleflex Incorporated (NYSE:TFX) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a report issued on Tuesday.

TFX has been the subject of a number of other research reports. Barclays PLC reiterated a “buy” rating on shares of Teleflex in a research report on Monday, June 26th. Needham & Company LLC reiterated a “buy” rating on shares of Teleflex in a research report on Friday. Zacks Investment Research upgraded shares of Teleflex from a “hold” rating to a “buy” rating and set a $228.00 target price for the company in a research report on Friday, June 23rd. Deutsche Bank AG increased their target price on shares of Teleflex from $213.00 to $220.00 and gave the company a “buy” rating in a research report on Monday, May 8th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $230.00 target price on shares of Teleflex in a research report on Thursday, August 3rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. Teleflex currently has an average rating of “Buy” and a consensus price target of $221.17.

Shares of Teleflex (NYSE:TFX) traded down 0.6756% during mid-day trading on Tuesday, hitting $213.1501. 97,679 shares of the company traded hands. The firm has a 50-day moving average price of $207.61 and a 200 day moving average price of $195.00. Teleflex has a 52-week low of $136.53 and a 52-week high of $216.37. The firm has a market cap of $9.59 billion, a price-to-earnings ratio of 44.2404 and a beta of 1.05.

Teleflex (NYSE:TFX) last announced its earnings results on Thursday, August 3rd. The medical technology company reported $2.04 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.91 by $0.13. The firm had revenue of $528.60 million during the quarter, compared to analyst estimates of $518.98 million. Teleflex had a net margin of 12.36% and a return on equity of 16.12%. Teleflex’s revenue was up 11.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.89 EPS. Equities research analysts anticipate that Teleflex will post $8.25 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/08/08/teleflex-incorporated-tfx-cut-to-sell-at-bidaskclub.html.

In other Teleflex news, Director Gretchen R. Haggerty purchased 1,000 shares of the business’s stock in a transaction on Wednesday, June 21st. The stock was bought at an average cost of $203.82 per share, with a total value of $203,820.00. Following the acquisition, the director now owns 1,760 shares of the company’s stock, valued at $358,723.20. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Stephen K. M.D. Klasko sold 200 shares of the company’s stock in a transaction dated Thursday, June 1st. The shares were sold at an average price of $199.93, for a total transaction of $39,986.00. Following the completion of the sale, the director now directly owns 8,080 shares of the company’s stock, valued at $1,615,434.40. The disclosure for this sale can be found here. Insiders sold a total of 8,300 shares of company stock valued at $1,643,975 over the last three months. 2.39% of the stock is owned by corporate insiders.

Large investors have recently modified their holdings of the stock. UBS Asset Management Americas Inc. increased its stake in shares of Teleflex by 118.9% in the fourth quarter. UBS Asset Management Americas Inc. now owns 72,560 shares of the medical technology company’s stock worth $11,692,000 after buying an additional 39,419 shares during the last quarter. Teachers Advisors LLC increased its stake in shares of Teleflex by 4.8% in the fourth quarter. Teachers Advisors LLC now owns 45,560 shares of the medical technology company’s stock worth $7,342,000 after buying an additional 2,074 shares during the last quarter. Creative Planning increased its stake in shares of Teleflex by 3.7% in the first quarter. Creative Planning now owns 2,259 shares of the medical technology company’s stock worth $438,000 after buying an additional 81 shares during the last quarter. Pennsylvania Trust Co increased its stake in shares of Teleflex by 0.7% in the first quarter. Pennsylvania Trust Co now owns 2,165 shares of the medical technology company’s stock worth $419,000 after buying an additional 15 shares during the last quarter. Finally, Fox Run Management L.L.C. acquired a new stake in shares of Teleflex during the first quarter worth $349,000. 93.02% of the stock is owned by institutional investors.

About Teleflex

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Analyst Recommendations for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.